
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is supported by a de-risked, expanding genomic diagnostics portfolio, with 3Q26 revenue of $151.8M up 15% Y/Y, adjusted EBITDA of $41.2M at a 27.2% margin, and free cash flow of $38.0M backed by $371M of cash and no debt. Its core franchises remain attractive because Decipher and Afirma still have meaningful penetration upside, while Prosigna and bladder-related tests provide additional operating leverage that could reaccelerate growth and support margin expansion beyond 2027. Although 2027 guidance for 5% revenue growth and ~22% EBITDA margin looks conservative, the company’s disciplined spending, product innovation, and strong commercial execution create multiple paths to upside as growth normalizes.
Bears say
Veracyte is facing a weakening fundamental profile because Decipher growth has decelerated, 3Q26 volume missed expectations, and management cut FY26 testing revenue guidance while resetting incremental annual Decipher growth to 12,000 to 15,000 tests from about 20,000. The company’s near-term growth is further pressured by low-risk guideline changes, DPAI-related rep distraction, and a FY27 framework that implies only mid-single-digit revenue growth and roughly 22% adjusted EBITDA margin, well below what the market expected. Although Afirma is outperforming and Prosigna, bladder, and TrueMRD add optionality, their current revenue contributions are modest, coverage is limited, and the planned ~30% urology commercial expansion should compress margins before those businesses can meaningfully offset the core slowdown.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Veracyte (VCYT) Forecast
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares